Autologous anti-KRAS G12V mTCR gene-engineered cell therapy (National Cancer Institute)

N/A

Report date: 2024/02/10 20:00:40

Base Information

Drug NameAutologous anti-KRAS G12V mTCR gene-engineered cell therapy (National Cancer Institute)
Drug Alias Nameanti-KRAS G12V mTCRanti-KRAS G12V/HLA-A*1101 TCR T-cell therapy (National Cancer Institute)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derived +[4] 
Mechanisms of ActionKRAS G12V modulators
TargetsKRAS G12V
Therapy Area/IndicationsPancreatic NeoplasmsStomach NeoplasmsRectal Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsStomach NeoplasmsRectal Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A